Compare KINS & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KINS | VYGR |
|---|---|---|
| Founded | 1886 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.7M | 227.2M |
| IPO Year | 2013 | 2015 |
| Metric | KINS | VYGR |
|---|---|---|
| Price | $15.83 | $3.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 127.2K | ★ 511.1K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.18% | N/A |
| EPS Growth | ★ 94.59 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $214,867,301.00 | $10,135,000.00 |
| Revenue This Year | $24.23 | $34.04 |
| Revenue Next Year | $18.05 | $7.92 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 38.50 | N/A |
| 52 Week Low | $13.08 | $2.65 |
| 52 Week High | $19.42 | $5.55 |
| Indicator | KINS | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 51.19 | 47.93 |
| Support Level | $15.64 | $3.71 |
| Resistance Level | $17.28 | $4.39 |
| Average True Range (ATR) | 0.75 | 0.27 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 72.57 | 40.23 |
Kingstone Companies Inc offers property and casualty insurance products through its subsidiary engaged in writing business through retail and wholesale agents and brokers. Its products include Personal lines, Livery physical damage, and Others. It operates in single segment, property and casualty insurance. It derives substantially all of its revenue from KICO, including revenues from earned premiums, ceding commissions from quota share reinsurance, net investment income generated from its investment portfolio, and net realized gains and losses on investment securities.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.